Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

Mergers and Acquisitions - Harbin Pharmaceutical Group plans to acquire 42.82% equity of Sanjing Qianhe Pharmaceutical for 23.446 million yuan [1] - Xinjiang Torch intends to purchase 100% equity of Yushan Litai for 125 million yuan, which is classified as a related party transaction but not a major asset restructuring [2] Share Buybacks - Rongxin Culture announces a share buyback plan with a budget between 20 million and 22 million yuan, with a maximum buyback price of 37 yuan per share [3] - Weifu High Science plans to repurchase shares with a budget of 100 million to 150 million yuan, with a maximum buyback price of 35 yuan per share [4] Shareholding Changes - Hubei Yihua's controlling shareholder plans to increase its stake in the company by investing between 200 million and 400 million yuan within six months starting from May 19, 2025, without a price range [5] - Fuchuang Precision announces that two shareholders plan to collectively reduce their holdings by up to 4% of the total shares [6] - Hanchuan Intelligent's controlling shareholder received a warning from Jiangsu Securities Regulatory Commission for failing to disclose significant risks related to pledge contracts [7] - Delin Hai's shareholder plans to reduce holdings by up to 3% of the total shares due to personal financial needs [8]

Investment Overview - The company’s wholly-owned subsidiary, Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. (Sanjing Pharmaceutical), plans to acquire 42.82% equity of Harbin Pharmaceutical Group Sanjing Qianhe Pharmaceutical Co., Ltd. (Qianhe Pharmaceutical) from three natural persons for a total investment of 23.446 million RMB [1][2] - The funding for this acquisition will come from Sanjing Pharmaceutical's own funds [1] Financial Metrics - The investment amount of 23.446 million RMB represents approximately 0.438% of the company's latest audited net assets of 5,349.7795 million RMB [1] - Qianhe Pharmaceutical's financial indicators for the year ending December 31, 2024, include total assets of 104.2393 million RMB, net assets of 7.9667 million RMB, operating income of 55.0289 million RMB, and net profit of 0.3907 million RMB [2] Shareholding Structure - Prior to the acquisition, Sanjing Pharmaceutical held 57.18% of Qianhe Pharmaceutical, and after the acquisition, it will become the sole owner [1][2] Strategic Importance - The acquisition aligns with national support policies for traditional Chinese medicine and will enhance the company's Chinese medicine segment, providing strategic synergy [5] - Qianhe Pharmaceutical has a product portfolio that includes 15 products, with 10 being traditional Chinese medicines and 3 unique varieties, indicating a strong market potential [5] Valuation and Pricing - The valuation of the minority shareholders' equity is approximately 23.6179 million RMB based on the audit report, and the market value of six pharmaceutical approvals held by Qianhe Pharmaceutical is estimated at 18.8610 million RMB [4][5] Impact on the Company - The acquisition is expected to optimize resource allocation, improve industry layout, and enhance market competitiveness, contributing to the company's long-term development and benefiting all shareholders [5]

公司全资子公司哈药集团三精制药有限公司（以下简称"三精制药"） 原持有哈药集团三精千鹤制药有限公司（以下简称"三精千鹤"）57.18% 的股权，董事会同意三精制药以2,344.60万元受让自然人持有的三精千鹤 将有利于优化资源配置、深化业务协同，进一步增强业务板块的市场竞争 力。公司董事会授权管理层具体办理本次对外投资相关事宜。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披 露的《哈药集团股份有限公司关于公司全资子公司收购股权的公告》（公 告编号：2025-019）。 证券代码:600664 证券简称:哈药股份 编号:临 2025-018 哈药集团股份有限公司 十届十四次董事会决议公告 本公 司董事 会及全 体董 事保证 公告内 容不存 在任何 虚假记 载、 误导性 陈述或 者重大 遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十四次 会议以书面方式发出通知，于 2025 年 5 月 15 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和 国公司法》和《公司章程》 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-020 交易简要内容：哈药集团股份有限公司（以下简称"公司"）拟通 过挂牌出租的方式对位于哈尔滨市道外区南直路 326 号的分公司哈药集 团制药六厂（以下简称"哈药六厂"）部分闲置厂房进行资产盘活。 根据《上海证券交易所股票上市规则》《上市公司重大资产重组管 理办法》，上述事项无须提交股东大会审议，也不构成关联交易和重大 资产重组。 相关风险提示：受政策、市场环境变化等因素影响，本次闲置资产 盘活方案在交易对方、交易价格及实施进度等方面仍存在不确定性，敬 请投资者理性决策，注意防范投资风险。 一、交易概述 为盘活存量闲置资产，提高资产使用效率，公司对位于哈尔滨市道 外区南直路 326 号的哈药六厂闲置厂房制定了综合规划方案，根据规划 方案，公司拟通过挂牌出租的方式对部分闲置厂房进行资产盘活。 公司于 2025 年 5 月 15 日召开第十届董事会第十四次会议，审议通 过了《关于公司分公司挂牌出租部分闲置资产的议案》，董事会同意对 分公司哈药六厂南直路部分闲置厂区及房产整体挂牌出租，授权公司管 理层开展后续挂牌以及合同签订等事项。本次授权决议的有效 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-019 哈药集团股份有限公司 关于公司全资子公司收购股权的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：哈药集团股份有限公司（以下简称"公司"）全资 子公司哈药集团三精制药有限公司（以下简称"三精制药"）拟收购三名 自然人所持有的哈药集团三精千鹤制药有限公司（以下简称"标的公司" 或"三精千鹤"）42.82%的股权。收购后，三精千鹤成为三精制药的全资 子公司。 投资金额：本次投资金额为 2,344.60 万元人民币，资金来源于三精 制药自有资金。 相关风险提示： 1、本次拟对外投资事项涉及的相关正式协议尚未签署，后续是否能签 署正式协议、交易能否最终完成尚存在不确定性。 2、本次股权收购实施后，标的公司是否能够高效、顺利运营并达成预 期目标存在一定的不确定性，可能面临行业、政策、市场环境变化及经营 管理等风险,投资收益存在不确定性，敬请投资者注意投资风险。 一、对外投资概述 近日，三精千鹤自然人股东就三精千鹤股权有关事宜提起诉讼 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-018 二、《关于公司分公司挂牌出租部分闲置资产的议案》（同意9票，反 对0票，弃权0票） 为了盘活公司资产，提高资产使用效率，根据房地产市场环境变化情 况，适时调整公司闲置资产处置策略，董事会同意对公司分公司哈药六厂 南直路部分闲置厂区及房产整体挂牌出租，授权公司管理层开展后续挂牌 哈药集团股份有限公司 十届十四次董事会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十四次 会议以书面方式发出通知，于 2025 年 5 月 15 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和 国公司法》和《公司章程》的有关规定，会议审议了如下议案： 一、《关于公司全资子公司收购股权的议案》（同意 9 票，反对 0 票，弃权 0 票） 公司全资子公司哈药集团三精制药有限公司（以下简称"三精制药"） 原持有哈药集团三精千鹤制药有限公司（以下简称"三精千鹤"）57.18 ...

哈药股份（600664）公告，公司全资子公司哈药集团三精制药有限公司拟收购三名自然人所持有的哈药 集团三精千鹤制药有限公司42.82%的股权，收购金额为2344.6万元人民币。收购完成后，三精千鹤将成 为三精制药的全资子公司。三精千鹤2024年营业收入5502.89万元，净利润39.07万元。 ...

Group 1: Company Overview - The company has seen significant revenue growth and steady profit improvement in its GNC China business, but there is still room for optimization in expense management [1] - The company plans to actively explore the potential of commercial contract promotion and implement various measures to reduce costs and improve efficiency, focusing on precise allocation of sales expenses [1] - The company aims to strengthen brand value and promote compliant, high-quality development of its GNC China business while closely monitoring market dynamics [1] Group 2: Market and Product Development - The orthopedic external patch market in China has exceeded 10 billion, with a compound annual growth rate of 9.55% driven by aging population and chronic disease management awareness [2] - The company is focusing on the development of traditional Chinese medicine combined with modern transdermal technology for its key prescription product, the wind-dispelling pain gel [2] - The company plans to continue digital and intelligent transformation of its traditional Chinese medicine production lines to enhance efficiency and responsiveness to national policy [2] Group 3: Future Product Pipeline - The company has received approval for a generic drug, lactulose oral solution, and is progressing with two other products through consistency evaluation [2] - Upcoming products expected to be approved in the next two years include oseltamivir phosphate dry suspension and iron protein succinate oral solution, among others [2] - The company will focus on major disease areas such as cardiovascular, digestive metabolism, respiratory, anti-infection, and anti-tumor, with an emphasis on developing medications for the elderly and children [2] Group 4: Financial Management - The company disclosed that its interest income comes solely from bank deposits, with no involvement in financial products or lending for interest income [3] - The company emphasizes a scientific and reasonable financial planning approach to maintain sufficient debt repayment capacity and a reasonable capital structure [3] - The company has established a budget management system to ensure that every expense has a responsible party and approval process, with regular evaluations and adjustments [3][4]

证券代码：600664 证券简称：哈药股份 编号：临 2025-017 哈药集团股份有限公司 会议召开地点："全景路演"网站（http://rs.p5w.net）、"全景财经" 微信公众号、"全景路演"APP 会议召开方式：网络远程方式 投资者可于 2025 年 5 月 7 日(星期三)至 5 月 13 日(星期二)16:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码进入问题征集专题页面，亦可将有 关问题通过电子邮件形式发送至公司邮箱：master@hayao.com，公司将在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 哈药集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日发布公司 2024 年度报告、2025 年第一季度报告。为了进一步加 强与投资者的互动交流，便于广大投资者更全面深入地了解公司经营 成果、财务状况，公司将参加由黑龙江省上市公司协会与深圳市全景 网络有限公司联合举办的"2025 年黑龙江辖区上市公司投资者集体 接待日活动"暨召开 2024 年度及 2025 年第一季度业绩说明会，在信 息披露允许的范围内就投资者普遍关注的问题进行 ...